Search

Mihalis S Kariolis

from Half Moon Bay, CA
Age ~37
Get Report
Related to:
Miguel Zara, 32Jacquelyn M Beresford, 35Michael J Dedovich, 53Vasilis S Kariolis, 35Stavros J Kariolis, 80Christopher M Dedovich, 55Christophe M Dedovich, 55Debra L Kariolis, 69Eleni S Kariolis, 41
Connected to:
Andrew Kariolic, 36Jason Kariotis, 49Madeline D Kariotis, 71Sally J Karioth, 77Rama Karipineni, 52Puja Karir, 46Chandresh R Karira, 42Jessica M Karira, 52Alyssa M Karis, 26Kyung L Karis, 75

Mihalis Kariolis Phones & Addresses

  • Half Moon Bay, CA
  • Millbrae, CA
  • San Mateo, CA
  • Palo Alto, CA
  • Troy, NY
  • West Hurley, NY

Work

Company: Stanford university school of medicine Aug 2013 to Nov 2015 Position: Stanford university school of medicine

Education

Degree: Master of Science, Masters School / High School: Stanford University 2008 to 2013 Specialities: Bioengineering

Skills

Cell Culture • Protein Engineering • Biomedical Engineering • Yeast Surface Display • Directed Evolution • Protein Purification • Flow Cytometry • Transfection • Cell Based Assays • Protein Expression • Protein Characterization • Confocal Microscopy • Microscopy • Cell • Biomaterials • Molecular Biology • Biochemistry • Biotechnology • Cell Biology • Research • Life Sciences • Pcr

Languages

English

Industries

Biotechnology

Resumes

Resumes

Mihalis Kariolis Photo 1

Scientist, Antibody And Protein Engineering

View page
Location:
107 Victoria Ave, Millbrae, CA 94030
Industry:
Biotechnology
Work:
Stanford University School of Medicine Aug 2013 - Nov 2015
Stanford University School of Medicine
Denali Therapeutics Aug 2013 - Nov 2015
Scientist, Antibody and Protein Engineering
Rensselaer Polytechnic Institute Mar 2007 - Jun 2008
Rensselaer Polytechnic Institute
Memorial Sloan Kettering Cancer Center Jun 2006 - Sep 2006
Memorial Sloan-Kettering Cancer Center
Education:
Stanford University 2008 - 2013
Master of Science, Masters, Bioengineering Rensselaer Polytechnic Institute 2004 - 2008
Bachelors, Bachelor of Science, Biomedical Engineering
Skills:
Cell Culture
Protein Engineering
Biomedical Engineering
Yeast Surface Display
Directed Evolution
Protein Purification
Flow Cytometry
Transfection
Cell Based Assays
Protein Expression
Protein Characterization
Confocal Microscopy
Microscopy
Cell
Biomaterials
Molecular Biology
Biochemistry
Biotechnology
Cell Biology
Research
Life Sciences
Pcr
Languages:
English

Publications

Us Patents

Cystine Knot Peptides Binding To Alpha Iib Beta 3 Integrins And Methods Of Use

View page
US Patent:
20110136740, Jun 9, 2011
Filed:
Nov 2, 2010
Appl. No.:
12/938216
Inventors:
Jennifer R. Cochran - Stanford CA, US
Adam P. Silverman - Redwood City CA, US
Mihalis S. Kariolis - Stanford CA, US
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
International Classification:
A61K 38/16
C07K 14/00
C07K 1/14
A61P 7/02
US Classification:
514 138, 530321, 514 211, 530300
Abstract:
Disclosed are peptides having a cystine knot structural motif and comprising a sequence engineered for specificity against αβintegrin, found on platelets, and a method of using the same in anti-thrombotic therapies. The present peptides utilize a cystine knot scaffold derived from modified agouti-related protein or agatoxin, An alternate library screening strategy was used to isolate variants of peptides that selectively bound to αβintegrin or to both αβand αβintegrins. Unique consensus sequences were identified within the identified peptides suggesting alternative molecular recognition events that dictate different integrin binding specificities. In addition, the engineered peptides prevented human platelet aggregation in a plasma-based assay and showed high binding affinity for αβintegrin.

Inhibition Of Axl Signaling In Anti-Metastatic Therapy

View page
US Patent:
20130017205, Jan 17, 2013
Filed:
Jul 20, 2012
Appl. No.:
13/554954
Inventors:
Amato J. Giaccia - Stanford CA, US
Erinn Bruno Rankin - Waltham MA, US
Jennifer R. Cochran - Stanford CA, US
Douglas Jones - Cambridge MA, US
Mihalis Kariolis - Stanford CA, US
Katherine Fuh - Palo Alto CA, US
Yu Miao - Sunnyvale CA, US
International Classification:
A61K 38/17
C07K 16/28
A61K 39/395
A61P 35/00
C12Q 1/68
C12N 5/10
C12N 5/12
C12N 1/19
G01N 33/574
C07K 14/705
A61P 35/04
US Classification:
4241391, 530350, 514 212, 5303879, 5303873, 435331, 4352542, 435 723, 435 612, 435 71, 436501
Abstract:
Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL and its ligand GAS6.

Inhibition Of Axl Signaling In Anti-Metastatic Therapy

View page
US Patent:
20130108644, May 2, 2013
Filed:
Aug 27, 2012
Appl. No.:
13/595936
Inventors:
Amato J. Giaccia - Stanford CA, US
Erinn Bruno Rankin - Waltham MA, US
Jennifer R. Cochran - Stanford CA, US
Douglas Jones - Cambridge MA, US
Mihalis Kariolis - Stanford CA, US
Katherine Fuh - Palo Alto CA, US
Yu Miao - Sunnyvale CA, US
International Classification:
C12N 9/12
C07K 16/22
A61K 45/06
A61K 38/45
US Classification:
4241581, 435194, 424 945, 5303892, 53038823, 5303873, 5303879, 435345, 435 612, 435 723
Abstract:
Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL and its ligand GAS6.

Inhibition Of Axl/Gas6 Signaling In The Treatment Of Disease

View page
US Patent:
20130189254, Jul 25, 2013
Filed:
Dec 14, 2012
Appl. No.:
13/714875
Inventors:
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA, US
Ruga Corporation - Palo Alto CA, US
Amato J. Giaccia - Stanford CA, US
Erinn Bruno Rankin - Waltham MA, US
Jennifer R. Cochran - Stanford CA, US
Douglas Jones - Cambridge MA, US
Mihalis Kariolis - Stanford CA, US
Katherine Fuh - Palo Alto CA, US
Yu Miao - Sunnyvale CA, US
Assignee:
Ruga Corporation - Palo Alto CA
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
International Classification:
C07K 14/47
C07K 16/28
C07K 16/40
C07K 16/18
C07K 19/00
US Classification:
4241341, 514 11, 514 154, 4241301, 4241361, 4241781, 4241841, 435 15, 435 61
Abstract:
Compositions and methods are provided for alleviating endometriosis, kidney disease, inflammatory disease and/or transplant rejection in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits AXL, MER or Tyro3 protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL, MER or Tyro3 and its ligand GAS6.

Inhibition Of Axl Signaling In Anti-Metastatic Therapy

View page
US Patent:
20140065143, Mar 6, 2014
Filed:
Jul 24, 2013
Appl. No.:
13/950111
Inventors:
Erinn Bruno Rankin - Waltham MA, US
Jennifer R. Cochran - Stanford CA, US
Douglas Jones - Cambridge MA, US
Mihalis Kariolis - Stanford CA, US
Katherine Fuh - Palo Alto CA, US
Yu Miao - Sunnyvale CA, US
Assignee:
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY - PALO ALTO CA
International Classification:
C07K 16/22
C07K 14/705
US Classification:
4241341, 5303873, 5303892, 4241581, 435336, 435 723
Abstract:
Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL and its ligand GAS6.

Fusion Proteins Comprising An Engineered Knottin Peptide And Uses Thereof

View page
US Patent:
20140073518, Mar 13, 2014
Filed:
Nov 7, 2011
Appl. No.:
13/883216
Inventors:
Jennifer R. Cochran - Stanford CA, US
Douglas S. Jones - Cambridge MA, US
Mihalis S. Kariolis - Stanford CA, US
Ping-Chuan Tsai - Fremont CA, US
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
International Classification:
C07K 14/705
C07K 14/47
C07K 14/475
C07K 14/81
US Classification:
506 9, 530350, 4352551
Abstract:
The present disclosure presents a general approach to engineering existing protein-protein interactions through domain addition and evolution. The disclosure teaches the creation of novel fusion proteins that include knottin peptides where a portion of the knottin peptide is replaced with a sequence that has been created for binding to a particular target. Such fusion proteins can also be bispecific or multi specific in that they can bind to and/or inhibit two or more receptors or receptor ligands. Knottins may be fused with an existing ligand (or receptor) as a general platform for increasing the affinity of a ligand-receptor interaction or for creating a multi specific protein. In addition, the fusion proteins may comprise a knottin peptide fused to another protein where the other protein facilitates proper expression and folding of the knottin.

Receptor-Based Antagonists Of The Programmed Cell Death 1 (Pd-1) Pathway

View page
US Patent:
20220378873, Dec 1, 2022
Filed:
Jun 24, 2022
Appl. No.:
17/849561
Inventors:
- STANFORD CA, US
Mihalis S. KARIOLIS - Stanford CA, US
Todd A. AGUILERA - Stanford CA, US
Assignee:
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY - STANFORD CA
International Classification:
A61K 38/17
C07K 14/705
A61P 31/22
A61P 31/12
A61P 31/20
A61P 31/14
A61P 31/18
A61P 31/04
A61P 35/04
A61P 31/10
A61K 45/06
Abstract:
Provided herein are compositions and methods for alleviating cancer or infection in a subject by administering a therapeutically effective amount of a pharmaceutical composition comprising an isolated PD-1 variant polypeptide. The PD-1 variant polypeptide can inhibit the activity of PD-1 by, for example, competitive or non-competitive inhibition of the interaction between wild-type PD-1 and one or more of its ligands, PD-L1 and PD-L2.

Modified Axl Peptides And Their Use In Inhibition Of Axl Signaling In Anti-Metastatic Therapy

View page
US Patent:
20220220458, Jul 14, 2022
Filed:
Sep 2, 2021
Appl. No.:
17/465203
Inventors:
- Stanford CA, US
- Houston TX, US
Jennifer R. Cochran - Stanford CA, US
Douglas Jones - Newton MA, US
Mihalis Kariolis - San Mateo CA, US
Katherine Cynthia Fuh - St. Louis MO, US
Yu Miao - Sunnyvale CA, US
Susan Hershenson - Palo Alto CA, US
International Classification:
C12N 9/12
C07K 16/46
A61K 45/06
Abstract:
Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL, MER or Tyro3 protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL, MER or Tyro3 and its ligand GAS6.
Control profile
Mihalis S Kariolis from Half Moon Bay, CA, age ~37 Get Report